A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Urticaria
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2017 This trial has been completed in Greece. (end date: 2017-06-12)
    • 15 Jun 2017 This trial has been completed in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top